Brookline Capital Management Comments on KYMR Q2 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at Brookline Capital Management issued their Q2 2025 EPS estimates for Kymera Therapeutics in a research note issued to investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings of ($0.97) per share for the quarter. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics' Q3 2025 earnings at ($1.03) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million.

Several other research analysts have also weighed in on the stock. Leerink Partners reaffirmed an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. BTIG Research began coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They set a "buy" rating and a $60.00 price objective for the company. HC Wainwright boosted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Stephens restated an "overweight" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, Wells Fargo & Company upgraded Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $56.69.

Remove Ads

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded up $0.84 during midday trading on Monday, reaching $32.54. 684,174 shares of the company's stock were exchanged, compared to its average volume of 582,709. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -13.91 and a beta of 2.22. Kymera Therapeutics has a fifty-two week low of $29.07 and a fifty-two week high of $53.27. The firm's 50 day simple moving average is $38.23 and its two-hundred day simple moving average is $43.40.

Insider Buying and Selling

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now directly owns 54,826 shares of the company's stock, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,788 shares of company stock worth $455,202 over the last 90 days. 15.82% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Kymera Therapeutics in the fourth quarter valued at $4,610,000. GF Fund Management CO. LTD. acquired a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $55,000. Woodline Partners LP grew its position in shares of Kymera Therapeutics by 2.3% during the fourth quarter. Woodline Partners LP now owns 537,428 shares of the company's stock worth $21,621,000 after acquiring an additional 12,334 shares during the last quarter. Vident Advisory LLC acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at $236,000. Finally, State of Wyoming acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at $45,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.